ClinicalTrials.gg
RecruitingNCT03546309RIC-PMDUpdated Nov 12, 2026

Safety and Efficacy of RIC in Pediatric Moyamoya Disease Patients Treated With Revascularization Therapy

An interventional study of RIC group and Medication group in Moyamoya Disease and Pediatric, sponsored by Capital Medical University. Recruiting at 1 site in China. Open to participants aged Up to 18 Years. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Capital Medical University · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Sep 2024; still recruiting 2 years 2 months later.
Updated Nov 12, 2026Primary completion movedStudy completion moved+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
98
Allocation
Randomized
Ages
Up to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 32 studies in Moyamoya Disease with a site in China — 17 open to participants now, 17 under way, none of them phase 3. Moyamoya Disease · China.

Planned enrollment
9th of 17
98 · median 98
Started
2024
with 5 others
No phase
11 of 32
3 open now
Primary completion
2026-11
later than 5 of 16 live
Registered
4th of 32
by date
Lead sponsor
4 of 32
Capital Medical University

Among the 32 studies in Moyamoya Disease with a site in China, this one is the 9th largest by planned enrollment of the 17 interventional ones that give a count, is one of 6 that started in 2024, is one of 11 with no phase, reaches primary completion later than 5 of the 16 other live ones, and was the 4th registered.

Moyamoya Disease

62 studies on the registry are indexed under Moyamoya Disease; 30 are open to participants now.

Browse Moyamoya Disease studies →

Open to participants now

17 of the 32 studies in Moyamoya Disease with a site in China are open now. Recruiting first, the newest first:

11 more — sign in →

All 17 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 22 Moyamoya Disease studies recruiting now, 9 (41%) set no upper age limit and 10 (45%) stop at 75 or younger; 9 take children under 18; 5 take healthy volunteers.

This study: Up to 18 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 32 studies in Moyamoya Disease with a site in China, or all of them as a file.
02

Study summary

Revascularization surgery has been the standard treatment to prevent ischemic stroke in pediatric Moyamoya disease (MMD) patients with ischemic symptoms. However, perioperative complications, such as hyperperfusion syndrome, new infarct on imaging, or ischemic stroke, are inevitable. Remote ischemic conditioning (RIC) is a noninvasive and easy-to-use neuroprotective strategy, and it has potential effects on preventing hyperperfusion syndrome and ischemic infarction.

Read the detailed description

This study will provide insights into the preliminary proof of principle, safety, and efficacy of RIC in pediatric MMD patients undergoing revascularization surgery therapy, and this data will provide parameters for future larger scale clinical trials if efficacious.

03

Conditions studied

  • Moyamoya Disease
  • Pediatric

Browse trials for

Keywords

  • pediatric moyamoya disease
  • remote ischemic conditioning
  • revascularization therapy
04

Who can participate

Ages eligible
Up to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age: ≥0 and ≤18
  • All of the patients underwent digital subtraction angiography and met the current diagnostic criteria recommended by the Research Committee on MMD (Spontaneous Occlusion of the Circle of Willis) of the Ministry of Health and Welfare of Japan in 2012
  • Suzuki stages concentrated in Stage III and IV
  • Presentation with ischemic symptoms, such as (TIA), headache, seizure, hemorrhagic stroke, and ischemic stroke confirmed by MRI
  • obtained from patient or acceptable patient's surrogate

Exclusion criteria

Exclusion Criteria:

  • Severe hepatic or renal dysfunction
  • Severe hemostatic disorder or severe coagulation dysfunction
  • Patients with unilateral MMD or the presence of secondary moyamoya phenomenon caused by disease, Down syndrome, neurofibromatosis, leptospiral infection, or previous skull-base radiation therapy
  • Any of the following cardiac disease - rheumatic mitral and or aortic stenosis, prosthetic heart valves, atrial fibrillation, atrial flutter, sick sinus syndrome, left atrial myxoma, patent foramen ovale, left ventricular mural thrombus or valvular vegetation, congestive heart failure, bacterial endocarditis, or any other cardiovascular condition interfering with participation
  • Serious, advanced, or terminal illnesses with anticipated of less than one year
  • Patient participating in a study involving other drug or device trial study
  • Patients with existing neurological or psychiatric disease that would confound the neurological or functional evaluations
  • Unlikely to be available for follow-up for 3 months
  • for RIC - severe soft-tissue injury, fracture, or peripheral vascular disease in the upper limbs.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
98 participants (estimated)

Study arms

  • Experimental
    RIC group

    Patients allocated to the RIC group will undergo RIC procedure during which bilateral arm cuffs are inflated to a pressure of 50 mmHg over systolic blood pressure for five cycles of 5 min followed by 5 min of relaxation of the cuffs.They will also accept medication treatment by professional neurologists.

    Device: RIC group

  • Other
    Medication group

    Patients allocated to the medication group will accept medication treatment by professional neurologists.

    Other: Medication group

Interventions

  • DeviceRIC group

    Patients allocated to the RIC group will undergo RIC procedure during which bilateral arm cuffs are inflated to a pressure of 50 mmHg over systolic blood pressure for five cycles of 5 min followed by 5 min of relaxation of the cuffs.

  • OtherMedication group

    Patients allocated to Medication group will accept medication treatment by professional neurologists

06

What researchers measure

Primary outcomes

  1. the incidence of major neurologic complications

    Including transient ischemic attack, cerebral infarction, intracranial hemorrhage, and seizures.

    Time frame: during the perioperative period

Secondary outcomes

  1. The score of National Institute of Health stroke scale score

    National Institute of Health Stroke Scale (NIHSS) is considered as a standardized assessment of neurological functions in the acute phase of stroke, and it is generally used to quantify patient's neurological impairments on 15 items in 11 fields of different neurological status.The score of the scale ranges from 0 to 42.And higher score indicates worse neurological function.

    Time frame: change from baseline (preoperation) at 24 hours, 48 hours, 72 hours, and at 5-7 days or if discharged earlier

  2. The score of Modified Rankin scale score

    The Modified Rankin Scale Score (mRS) is the most comprehensive and most widely used primary outcome measurement to assess the neurological functional disability in contemporary acute stroke trials. The mRS is an ordinal, graded interval scale that assigns patients among 7 global disability levels, which ranges from 0 (no symptom) to 5 (severe disability) and 6 (death). We will use mRS to evaluate the degree of disability or dependence during daily activities. The mRS will be assessed by certified study investigator, who is blinded to the treatment assignment, at 90 days postoperation. The distribution of mRS will be compared between groups

    Time frame: change from baseline (pre-RIC treatment) at 180 days after revascularization therapy

  3. Symptomatic intracerebral hemorrhage

    Symptomatic intracranial hemorrhage, including any subarachnoid hemorrhage associated with clinical symptoms and symptomatic intracerebral hemorrhage. Head computed tomography or magnetic reasoning imaging (MRI) scan will be performed to confirm intracerebral hemorrhage, and the imaging will be evaluated by two independent neuroradiologists who are blinded to the study assignment.

    Time frame: during the first 180 days after revascularization therapy

  4. Incidence of new infarct in brain

    Head MRI is a precise method which is commonly used to evaluate weather there's new infarct in brain.

    Time frame: during 72 hours and 180 days after revascularization therapy

  5. Angiographic outcome

    Angiographic outcome will be assessed following Matsushima's criteria (proportion of the middle cerebral artery territory with revascularization from collaterals from the external carotid artery through the burr holes): Grade A: \>2/3; Grade B: between 1/3 and 2/3; Grade C: \<1/3.

    Time frame: 180 days after revascularization therapy

  6. Death and adverse event

    All causes of death will be included to compute mortality at 180 days postoperation, and mortality will be compared between groups. Any adverse event will be reported and its relationship with the RIC intervention will be evaluated.

    Time frame: 180 days after revascularization therapy

  7. Infarct volume in brain

    Head MRI is a precise method which is commonly used to evaluate infarct size.

    Time frame: during 72 hours and 180 days after revascularization therapy

  8. Distal radial pulses

    professional doctors will check the distal radial pulses

    Time frame: within 7 days after RIC treatment

  9. Visual inspection for local edema

    Professional oculists will check the fundus oculi to evaluate whether there is local edema.

    Time frame: within 7days after RIC treatment

  10. The number of patients with erythema,and/or skin lesions related to RIC

    Professional doctors will check it and the investigator will record the number.

    Time frame: within 7days after RIC treatment

  11. Palpation for tenderness

    Professional doctors will check it.

    Time frame: within 7days after RIC treatment

  12. The number of patients not tolerating RIC procedure,and refuse to continue the RIC procedure

    The investigator will record the number.

    Time frame: within 7days after RIC treatment

  13. The number of patients with any other adverse events related to RIC intervention

    The investigator will record the number.

    Time frame: within 7days after RIC treatment

  14. The score of ABCD2

    We use this scale to evaluate the patients' risk of stroke who with TIA .The score of the scale ranges from 0 to 7, and the higher score indicates higher risk of stroke in the patients who with TIA.The scale will be assessed by qualified investigator who are blinded to the treatment assignment

    Time frame: change from baseline (pre-RIC treatment) at 180 days after revascularization therapy

  15. The level of S-100A4

    Blood samples will be drawn from cubital vein to test these biomarkersThese samples will be centrifuged immediately after collection and stored at - 80 until batch evaluation

    Time frame: change from baseline (pre-RIC treatment) at 7 days after RIC treatment, 24 (-6/+12) hours, 72 ± 6 hours and 6 months postoperation

  16. The level of matrix metalloproteinase 9 (MMP-9)

    Blood samples will be drawn from cubital vein to test these biomarkersThese samples will be centrifuged immediately after collection and stored at - 80 until batch evaluation

    Time frame: change from baseline (pre-RIC treatment) at 7 days after RIC treatment, 24 (-6/+12) hours, 72 ± 6 hours and 6 months post-operation

  17. The level of basic fibroblast growth factor

    Blood samples will be drawn from cubital vein to test these biomarkersThese samples will be centrifuged immediately after collection and stored at - 80 until batch evaluation

    Time frame: change from baseline (pre-RIC treatment) at 7 days after RIC treatment, 24 (-6/+12) hours, 72 ± 6 hours and 6 months post-operation

  18. The level of platelet derived growth factor

    Blood samples will be drawn from cubital vein to test these biomarkersThese samples will be centrifuged immediately after collection and stored at - 80 until batch evaluation

    Time frame: change from baseline (pre-RIC treatment) at 7 days after RIC treatment, 24 (-6/+12) hours, 72 ± 6 hours and 6 months post-operation

  19. The level of vascular endothelial growth factor

    Blood samples will be drawn from cubital vein to test these biomarkersThese samples will be centrifuged immediately after collection and stored at - 80 until batch evaluation

    Time frame: change from baseline (pre-RIC treatment) at 7 days after RIC treatment, 24 (-6/+12) hours, 72 ± 6 hours and 6 months post-operation

  20. the score of PSQI

    The Pittsburgh Sleep Quality Index (PSQI) is a standardized questionnaire used to assess sleep quality and disturbances over a one-month time interval.

    Time frame: 0-30 days

  21. the score of SNAP-IV

    SNAP-IV (Swanson, Nolan, and Pelham Teacher and Parent Rating Scale) is a widely used assessment tool designed to evaluate behavioral and emotional problems in children and adolescents.

    Time frame: 0-30 days

  22. cerebral perfusion status

    cerebral perfusion status in the operation side at 3 months posttreatment as assessed by magnetic resonance perfusion

    Time frame: 0-3 months

07

Study locations

1 of 1 sites recruiting
  • The Fifth Medical Center of Chinese PLA General Hospital
    Beijing, Beijing Municipality, China
    Recruiting
    • xunming Ji · Contact
08

References and documents

Publications

  • Kuriyama S, Kusaka Y, Fujimura M, Wakai K, Tamakoshi A, Hashimoto S, Tsuji I, Inaba Y, Yoshimoto T. Prevalence and clinicoepidemiological features of moyamoya disease in Japan: findings from a nationwide epidemiological survey. Stroke. 2008 Jan;39(1):42-7. doi: 10.1161/STROKEAHA.107.490714. Epub 2007 Nov 29. PubMed 18048855 ↗
  • Kim SK, Seol HJ, Cho BK, Hwang YS, Lee DS, Wang KC. Moyamoya disease among young patients: its aggressive clinical course and the role of active surgical treatment. Neurosurgery. 2004 Apr;54(4):840-4; discussion 844-6. doi: 10.1227/01.neu.0000114140.41509.14. PubMed 15046649 ↗
  • Kim JE, Oh CW, Kwon OK, Park SQ, Kim SE, Kim YK. Transient hyperperfusion after superficial temporal artery/middle cerebral artery bypass surgery as a possible cause of postoperative transient neurological deterioration. Cerebrovasc Dis. 2008;25(6):580-6. doi: 10.1159/000132205. Epub 2008 May 16. PubMed 18483458 ↗
  • Fujimura M, Shimizu H, Inoue T, Mugikura S, Saito A, Tominaga T. Significance of focal cerebral hyperperfusion as a cause of transient neurologic deterioration after extracranial-intracranial bypass for moyamoya disease: comparative study with non-moyamoya patients using N-isopropyl-p-[(123)I]iodoamphetamine single-photon emission computed tomography. Neurosurgery. 2011 Apr;68(4):957-64; discussion 964-5. doi: 10.1227/NEU.0b013e318208f1da. PubMed 21221039 ↗
  • Funaki T, Takahashi JC, Takagi Y, Kikuchi T, Yoshida K, Mitsuhara T, Kataoka H, Okada T, Fushimi Y, Miyamoto S. Unstable moyamoya disease: clinical features and impact on perioperative ischemic complications. J Neurosurg. 2015 Feb;122(2):400-7. doi: 10.3171/2014.10.JNS14231. Epub 2014 Nov 28. PubMed 25423271 ↗
  • Zhao W, Meng R, Ma C, Hou B, Jiao L, Zhu F, Wu W, Shi J, Duan Y, Zhang R, Zhang J, Sun Y, Zhang H, Ling F, Wang Y, Feng W, Ding Y, Ovbiagele B, Ji X. Safety and Efficacy of Remote Ischemic Preconditioning in Patients With Severe Carotid Artery Stenosis Before Carotid Artery Stenting: A Proof-of-Concept, Randomized Controlled Trial. Circulation. 2017 Apr 4;135(14):1325-1335. doi: 10.1161/CIRCULATIONAHA.116.024807. Epub 2017 Feb 7. PubMed 28174194 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Sep 2024 (actual). Primary completion is estimated for Nov 2026, 26 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 12, 2026: primary completion Dec 2024 → Nov 2026 and completion Feb 2025 → Nov 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 12, 2018
First posted
Jun 6, 2018
StartActual
Sep 10, 2024
Primary completionEst.
Nov 18, 2026was Dec 2024
CompletionEst.
Nov 18, 2026was Feb 2025
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added, 1 site removed
Show site
  • The Fifth Medical Center of Chinese PLA General Hospital · Beijing, China
Show 1 removed
  • The Fifth Medical Center of Chinese PLA General Hospital · Beijing, China
Nov 12, 2026
Primary completion
Dec 30, 2024→Nov 18, 2026
Nov 12, 2026
Study completion
Feb 28, 2025→Nov 18, 2026
Nov 12, 2026
Enrollment
42→98
Nov 12, 2026
Sponsor
Collaborators added: Beijing 302 Hospital; collaborators removed: The Fifth Medical Center of the Chinese People's Liberation Army (PLA) General Hospital
Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    1 site added, 1 site removed
    Show site
    • The Fifth Medical Center of Chinese PLA General Hospital · Beijing, China
    Show 1 removed
    • The Fifth Medical Center of Chinese PLA General Hospital · Beijing, China
    Primary completion Dec 30, 2024→Nov 18, 2026
    Study completion Feb 28, 2025→Nov 18, 2026
    Enrollment 42→98
    Sponsor Collaborators added: Beijing 302 Hospital; collaborators removed: The Fifth Medical Center of the Chinese People's Liberation Army (PLA) General Hospital
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT03546309
Collaborators
Beijing 302 Hospital
Responsible party
Ji Xunming,MD,PhD (Professor, Capital Medical University) — Principal investigator
First posted
Jun 6, 2018
Start date
Sep 10, 2024
Primary completion
Nov 18, 2026 (estimated)
Completion
Nov 18, 2026 (estimated)
Last update
Nov 12, 2026

Study contacts

Xunming Ji, MD PhD
Contact
807595234@qq.com;
+8613911077166
Sijie Li, MD
Contact
phoenix0537@sina.com
+8613581610258

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion